Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients

Kim Leitzel, Yoshio Teramoto, Ellen Sampson, June Mouceri, Beatrice C. Langten, Laurence Demers, Edward Podczaski, Harold Harvey, Shown Shambaugh, Gena Volas, Susan Weaver, Allan Lipton

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Purpose: An enzyme-linked immunosorbent assay (ELISA) for the extracellular domain of the c-erbB-2 oncogene product was developed and evaluated to determine if soluble c-erbB-2 could be detected in the serum and effusions of cancer patients. Patients and Methods: Sera from 208 previously untreated or progressing cancer patients and 69 healthy controls were assayed in a double-antibody sandwich ELISA that used two monoclonal antibodies to the native extracellular domain of the c-erbB-2 receptor. Fisher's exact test was used to analyze the statistical significance of the frequency of elevated serum c-erbB-2 levels. Immunoprecipitation and Western blotting were used to characterize further the c-erbB-2 immunoreactivity in the serum of four breast cancer patients. Results: Sera from 12 of 53 patients (23%) with metastatic or locally advanced breast cancer, zero of 69 controls, one of 31 patients with ovarian cancer (3%), and two of 124 other cancer patients (2%) had soluble c-erbB-2 values > to 5 U /mL. The number of breast cancer patients with elevated serum c-erbB-2 levels was significantly greater than that of the control group (P > .0001), the ovarian cancer group (P < .03), and the other cancers group (P < .0001). Also, two of five effusions (40%) from breast cancer patients had an elevated soluble c-erbB-2 antigen level, compared with zero of 17 effusions from patients with benign diseases. Western blotting of four sera from breast cancer patients with elevated serum c-erbB-2 antigen levels produced bands of approximately 105 kD that seemed to correlate in intensity with increasing ELISA serum levels. Conclusion: Serum c-erbB-2 levels are elevated in approximately one fourth of patients with locally advanced or metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)1436-1443
Number of pages8
JournalJournal of Clinical Oncology
Volume10
Issue number9
DOIs
StatePublished - Jan 1 1992

Fingerprint

Breast Neoplasms
Antigens
Serum
Enzyme-Linked Immunosorbent Assay
Ovarian Neoplasms
Neoplasms
Western Blotting
ErbB-2 Receptor
Oncogene Proteins
Immunoprecipitation
Monoclonal Antibodies
Control Groups
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Leitzel, Kim ; Teramoto, Yoshio ; Sampson, Ellen ; Mouceri, June ; Langten, Beatrice C. ; Demers, Laurence ; Podczaski, Edward ; Harvey, Harold ; Shambaugh, Shown ; Volas, Gena ; Weaver, Susan ; Lipton, Allan. / Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. In: Journal of Clinical Oncology. 1992 ; Vol. 10, No. 9. pp. 1436-1443.
@article{b55c74f99443418b9d11ec06234dfa7e,
title = "Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients",
abstract = "Purpose: An enzyme-linked immunosorbent assay (ELISA) for the extracellular domain of the c-erbB-2 oncogene product was developed and evaluated to determine if soluble c-erbB-2 could be detected in the serum and effusions of cancer patients. Patients and Methods: Sera from 208 previously untreated or progressing cancer patients and 69 healthy controls were assayed in a double-antibody sandwich ELISA that used two monoclonal antibodies to the native extracellular domain of the c-erbB-2 receptor. Fisher's exact test was used to analyze the statistical significance of the frequency of elevated serum c-erbB-2 levels. Immunoprecipitation and Western blotting were used to characterize further the c-erbB-2 immunoreactivity in the serum of four breast cancer patients. Results: Sera from 12 of 53 patients (23{\%}) with metastatic or locally advanced breast cancer, zero of 69 controls, one of 31 patients with ovarian cancer (3{\%}), and two of 124 other cancer patients (2{\%}) had soluble c-erbB-2 values > to 5 U /mL. The number of breast cancer patients with elevated serum c-erbB-2 levels was significantly greater than that of the control group (P > .0001), the ovarian cancer group (P < .03), and the other cancers group (P < .0001). Also, two of five effusions (40{\%}) from breast cancer patients had an elevated soluble c-erbB-2 antigen level, compared with zero of 17 effusions from patients with benign diseases. Western blotting of four sera from breast cancer patients with elevated serum c-erbB-2 antigen levels produced bands of approximately 105 kD that seemed to correlate in intensity with increasing ELISA serum levels. Conclusion: Serum c-erbB-2 levels are elevated in approximately one fourth of patients with locally advanced or metastatic breast cancer.",
author = "Kim Leitzel and Yoshio Teramoto and Ellen Sampson and June Mouceri and Langten, {Beatrice C.} and Laurence Demers and Edward Podczaski and Harold Harvey and Shown Shambaugh and Gena Volas and Susan Weaver and Allan Lipton",
year = "1992",
month = "1",
day = "1",
doi = "10.1200/JCO.1992.10.9.1436",
language = "English (US)",
volume = "10",
pages = "1436--1443",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

Leitzel, K, Teramoto, Y, Sampson, E, Mouceri, J, Langten, BC, Demers, L, Podczaski, E, Harvey, H, Shambaugh, S, Volas, G, Weaver, S & Lipton, A 1992, 'Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients', Journal of Clinical Oncology, vol. 10, no. 9, pp. 1436-1443. https://doi.org/10.1200/JCO.1992.10.9.1436

Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. / Leitzel, Kim; Teramoto, Yoshio; Sampson, Ellen; Mouceri, June; Langten, Beatrice C.; Demers, Laurence; Podczaski, Edward; Harvey, Harold; Shambaugh, Shown; Volas, Gena; Weaver, Susan; Lipton, Allan.

In: Journal of Clinical Oncology, Vol. 10, No. 9, 01.01.1992, p. 1436-1443.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients

AU - Leitzel, Kim

AU - Teramoto, Yoshio

AU - Sampson, Ellen

AU - Mouceri, June

AU - Langten, Beatrice C.

AU - Demers, Laurence

AU - Podczaski, Edward

AU - Harvey, Harold

AU - Shambaugh, Shown

AU - Volas, Gena

AU - Weaver, Susan

AU - Lipton, Allan

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Purpose: An enzyme-linked immunosorbent assay (ELISA) for the extracellular domain of the c-erbB-2 oncogene product was developed and evaluated to determine if soluble c-erbB-2 could be detected in the serum and effusions of cancer patients. Patients and Methods: Sera from 208 previously untreated or progressing cancer patients and 69 healthy controls were assayed in a double-antibody sandwich ELISA that used two monoclonal antibodies to the native extracellular domain of the c-erbB-2 receptor. Fisher's exact test was used to analyze the statistical significance of the frequency of elevated serum c-erbB-2 levels. Immunoprecipitation and Western blotting were used to characterize further the c-erbB-2 immunoreactivity in the serum of four breast cancer patients. Results: Sera from 12 of 53 patients (23%) with metastatic or locally advanced breast cancer, zero of 69 controls, one of 31 patients with ovarian cancer (3%), and two of 124 other cancer patients (2%) had soluble c-erbB-2 values > to 5 U /mL. The number of breast cancer patients with elevated serum c-erbB-2 levels was significantly greater than that of the control group (P > .0001), the ovarian cancer group (P < .03), and the other cancers group (P < .0001). Also, two of five effusions (40%) from breast cancer patients had an elevated soluble c-erbB-2 antigen level, compared with zero of 17 effusions from patients with benign diseases. Western blotting of four sera from breast cancer patients with elevated serum c-erbB-2 antigen levels produced bands of approximately 105 kD that seemed to correlate in intensity with increasing ELISA serum levels. Conclusion: Serum c-erbB-2 levels are elevated in approximately one fourth of patients with locally advanced or metastatic breast cancer.

AB - Purpose: An enzyme-linked immunosorbent assay (ELISA) for the extracellular domain of the c-erbB-2 oncogene product was developed and evaluated to determine if soluble c-erbB-2 could be detected in the serum and effusions of cancer patients. Patients and Methods: Sera from 208 previously untreated or progressing cancer patients and 69 healthy controls were assayed in a double-antibody sandwich ELISA that used two monoclonal antibodies to the native extracellular domain of the c-erbB-2 receptor. Fisher's exact test was used to analyze the statistical significance of the frequency of elevated serum c-erbB-2 levels. Immunoprecipitation and Western blotting were used to characterize further the c-erbB-2 immunoreactivity in the serum of four breast cancer patients. Results: Sera from 12 of 53 patients (23%) with metastatic or locally advanced breast cancer, zero of 69 controls, one of 31 patients with ovarian cancer (3%), and two of 124 other cancer patients (2%) had soluble c-erbB-2 values > to 5 U /mL. The number of breast cancer patients with elevated serum c-erbB-2 levels was significantly greater than that of the control group (P > .0001), the ovarian cancer group (P < .03), and the other cancers group (P < .0001). Also, two of five effusions (40%) from breast cancer patients had an elevated soluble c-erbB-2 antigen level, compared with zero of 17 effusions from patients with benign diseases. Western blotting of four sera from breast cancer patients with elevated serum c-erbB-2 antigen levels produced bands of approximately 105 kD that seemed to correlate in intensity with increasing ELISA serum levels. Conclusion: Serum c-erbB-2 levels are elevated in approximately one fourth of patients with locally advanced or metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0027095843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027095843&partnerID=8YFLogxK

U2 - 10.1200/JCO.1992.10.9.1436

DO - 10.1200/JCO.1992.10.9.1436

M3 - Article

C2 - 1355522

AN - SCOPUS:0027095843

VL - 10

SP - 1436

EP - 1443

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -